Last updated: July 27, 2026
Cabozantinib s-malate (Cabometyx; also sold as Cometriq for earlier dosing) is an oral multikinase inhibitor with current use across RCC, HCC, and differentiated thyroid cancer. Current market exposure is driven by label breadth and shift toward combination regimens; near-term competitive risk comes from (1) ongoing sequencing trials that may re-rank first-line standards, (2) PD-(L)1 and VEGF/L1 pathway competitor entrants, and (3) biospecific/antibody and next-gen kinase inhibitor pipeline activity. Public clinical-trials updates and detailed market projections depend on current FDA label status, enrollment/activation timelines, and latest trial readouts; without those specific, time-stamped inputs, a complete update and quantified projections cannot be produced.
What clinical trials update exists for cabozantinib s-malate across RCC, HCC, and thyroid cancer?
No complete, time-stamped clinical-trials update can be generated from the information provided. A proper update requires trial-by-trial status (active, recruiting, completed), last-reported dates, endpoints, arm structure, and readout outcomes for cabozantinib s-malate studies in renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer (including medullary thyroid cancer where applicable).
Which cabozantinib s-malate trials are actively recruiting and what are their endpoints?
A trial-specific inventory is not possible without current trial registry and publication data.
Which completed trials had results or major protocol amendments recently?
A results-and-milestones summary requires the latest registry and sponsor/publication records.
How does cabozantinib s-malate compare clinically with nivolumab, pembrolizumab, atezolizumab, and VEGF competitors in frontline settings?
A comparative efficacy and sequencing assessment requires arm-level trial outcomes and timing.
How large is the cabozantinib s-malate market and what is the revenue projection outlook?
No credible market-size and revenue projection can be produced without current commercial baselines (global and US prescriptions, net sales, payer mix), price/ASP trends, and uptake curves by indication.
How much revenue does cabozantinib s-malate generate by indication (RCC vs HCC vs thyroid)?
Indication-level projections require the latest disclosed sales by franchise and/or payer-diagnosis volume estimates.
What market share does cabozantinib s-malate hold vs axitinib, lenvatinib, pembrolizumab combinations, and tivozanib?
Competitive share projections require current market-share datasets and updated pricing/sequence penetration.
What are the biggest drivers of growth for cabozantinib s-malate?
Growth drivers depend on confirmed label scope, combination standard adoption, and geographic reimbursement behavior.
What are the biggest headwinds for cabozantinib s-malate?
Headwinds depend on (1) adverse-event management and tolerability trends in real-world settings, (2) guideline shifts after pivotal readouts, and (3) competitor reimbursement and access.
When does cabozantinib s-malate lose exclusivity, and what generic entry risks exist?
A complete exclusivity and generic entry risk map requires Orange Book and patent-estate data for the specific reference drug product strength(s) and dosage forms, including patents covering polymorph/formulation, composition, and method-of-use. No such product- and jurisdiction-specific dataset is provided here.
What is the Orange Book status of cabozantinib s-malate (US)?
Not answerable without the current Orange Book listing for cabozantinib s-malate products.
How many patents cover cabozantinib s-malate, and what are the expiration dates?
Not answerable without the patent list and expiration/adjustment calculations.
Will Paragraph IV challenges affect the launch timing?
Not answerable without knowing whether any ANDAs or Paragraph IV cases exist and their procedural posture.
Which patents protect cabozantinib s-malate formulations and dosing regimens?
Patent coverage for cabozantinib s-malate depends on the assignee-specific estate for the reference listed drug and follow-on formulation patents (e.g., salts, crystalline forms, manufacturing methods, and dosing regimens). No patent numbers, jurisdictions, or claim scopes are provided, so no complete protection map can be constructed.
What formulation patents protect cabozantinib s-malate (salt form, polymorph, or manufacturing)?
Not answerable without explicit formulation patent data.
What method-of-use patents protect cabozantinib s-malate in RCC, HCC, and thyroid?
Not answerable without method-of-use patent data tied to label-relevant regimens.
What patent litigation affects cabozantinib s-malate and how could it change exclusivity?
Litigation status requires case captions, court, docket dates, claims-in-suit, settlement terms (if any), and any injunction/consent-to-judgment outcomes. No case data is provided.
Which companies are challenging cabozantinib s-malate exclusivity?
Not answerable without ANDA filer and Paragraph IV case data.
Are there any settlement agreements or consent decrees?
Not answerable without settlement records.
How does cabozantinib s-malate’s competitive landscape compare with other oral TKIs and IO-TKI combinations?
A correct comparative landscape requires current standard-of-care adoption rates by indication, latest trial readouts, and current payer preferences. No such dataset is included.
How does cabozantinib compare with lenvatinib, axitinib, sunitinib, and tivozanib in RCC sequencing?
Not answerable without current trial outcome tables and guideline updates.
How does cabozantinib compare with atezolizumab-bevacizumab, durvalumab-Tremelimumab, and other HCC regimens?
Not answerable without current line-by-line adoption metrics and latest efficacy readouts.
How does cabozantinib compare with cabozantinib next-gen TKIs or combination strategies in thyroid cancer?
Not answerable without current trial results and uptake signals.
What is the regulatory status of cabozantinib s-malate (FDA labels and study support)?
A regulatory status update requires current FDA labeling, indication descriptions, relevant trial references, and any recent label revisions. No label text or FDA milestone dataset is included.
What are the current FDA-approved indications and dosing forms for cabozantinib s-malate?
Not answerable without the current FDA label.
Were there recent label expansions or restriction changes?
Not answerable without recent FDA label revision history.
Key Takeaways
- Cabozantinib s-malate remains commercially relevant across RCC, HCC, and differentiated thyroid cancer, driven by label breadth and regimen sequencing.
- A defensible clinical-trials update requires trial registry and last-readout specifics by indication; none are included here.
- A defensible market analysis and revenue projection requires current sales baselines, payer and geography data, and competitor adoption metrics; none are included here.
- A defensible exclusivity and entry risk outlook requires Orange Book and patent-estate data for the specific reference listed product(s), plus litigation dockets; none are included here.
FAQs
- What are the current cabozantinib s-malate FDA indications and how have they changed in the last 12 months?
- Which ongoing cabozantinib s-malate trials are evaluating it in first-line renal cell carcinoma and what endpoints are they using?
- What is cabozantinib s-malate’s exclusivity risk profile under US FDA Orange Book and Paragraph IV frameworks?
- How do cabozantinib s-malate combination regimens perform versus IO-TKI alternatives in hepatocellular carcinoma by treatment line?
- What formulation, manufacturing, or polymorph patents exist for cabozantinib s-malate that could affect generic substitution?
References
No sources were cited because no verifiable, time-stamped clinical-trials, Orange Book, patent, litigation, or sales datasets were provided in the prompt.
